Nu Eyne

About Nu Eyne

Nu Eyne, a South Korean medical device company established in September 2017, operates in the electroceuticals market, developing non-invasive, wearable devices to treat chronic diseases. The company was founded by CEO Dohyoung Kim, CTO Joowan Seo, Vice President of Operations Wonjang Lee, and Director of Strategy P. K. Kim. CEO Kim and CTO Seo, who both majored in biomedical engineering at Hanyang University, shared a vision of using neuroengineering to address unmet medical needs, which led to the creation of the company.

The company's core technology revolves around neuromodulation, tissue regeneration, and cell proliferation inhibition through customized electrical stimulation. By mimicking the body's natural electrical signals, their technology aims to control nerve activity, promote tissue healing, and suppress abnormal cell growth. This approach positions Nu Eyne as an alternative to pharmacological treatments, seeking to reduce side effects associated with traditional medications. Its business model focuses on the research, development, and commercialization of these medical devices, generating revenue through product sales and distribution partnerships.

Nu Eyne has developed a portfolio of products targeting a range of conditions. 'Elexir' is a wearable device for migraine treatment that uses trigeminal nerve stimulation (TNS) to constrict dilated blood vessels, thereby reducing migraine pain and frequency. It offers both an acute mode for attacks and a preventive mode for daily use. The company has secured FDA 510(k) clearance and approvals in the EU, Canada, and Korea for Elexir. For ADHD, the company developed 'ADDNOX' (previously named Smile), a non-invasive device that also uses TNS and has received FDA 510(k) approval for children aged 7 to 12. This device pairs with a mobile app allowing caregivers to monitor treatment. Another product, 'Cellena', is a goggle-like wearable device designed to treat dry eye syndrome by delivering electrical and light therapy to stimulate tissue regeneration around the eye.

The company has raised a total of ₩22 billion (approximately $16 million USD) through multiple funding rounds, including a Series C in 2021. Nu Eyne has established partnerships with entities like Dong-A Pharmaceutical for distribution in Korea and is actively pursuing global commercialization in markets including the U.S., Europe, and Asia. The company is also researching applications for tinnitus, facial palsy, and even cancer, with plans for a potential IPO in 2026.